1301
|
Keaveny AP, Karasik MS. Hepatobiliary and pancreatic infections in AIDS: Part one. AIDS Patient Care STDS 1998; 12:347-57. [PMID: 11361970 DOI: 10.1089/apc.1998.12.347] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Infections of the liver and biliary tract are common during the course of AIDS. A variety of viral, bacterial, fungal, and other opportunistic infections can present with hepatobiliary involvement as either the primary site of infection or secondary to a disseminated process. Coinfection with hepatitis B and C are particularly common due to the shared means of transmission of these viruses with HIV. The typical presenting features of hepatobiliary infections are right upper quadrant (RUQ) pain and abnormal liver function tests. Initial evaluation should include an RUQ ultrasonogram, which will usually identify abnormalities in the biliary tract and may demonstrate some parenchymal abnormalities as well. A liver biopsy is necessary to determine the etiology of focal hepatic lesions or opportunistic infections within hepatic parenchyma when other less invasive tests are negative or inconclusive. Special stains and culture techniques are required to identify specific organisms in the biopsy specimen. HIV-related biliary disorders include acalculous cholecystitis, which is a potentially serious condition requiring prompt recognition and gallbladder decompression. AIDS-cholangiopathy is a form of cholangitis involving the intra- and/or extrahepatic biliary tree. Endoscopic retrograde cholangio-pancreatography (ERCP) is the test of choice, demonstrating the stricturing, dilatation, and beading of bile ducts seen in this condition. Endoscopic sphincterotomy of the papilla of Vater may provide symptomatic relief for patients with papillary stenosis. Opportunistic infections of the pancreas have been reported. Evaluation should include a computerized tomogram of the abdomen and possible pancreatic tissue aspiration or biopsy. Management of pancreatitis is supportive.
Collapse
Affiliation(s)
- A P Keaveny
- Section of Gastroenterology, Boston Medical Center, Massachusetts, USA
| | | |
Collapse
|
1302
|
Burger DM, Hoetelmans RMW, Hugen PWH, Mulder JW, Meenhorst PL, Koopmans PP, Brinkman K, Keuter M, Dolmans W, Hekster YA. Low Plasma Concentrations of Indinavir are Related to Virological Treatment Failure in HIV-1-Infected Patients on Indinavir-Containing Triple Therapy. Antivir Ther 1998. [DOI: 10.1177/135965359800300401] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
All human immunodeficiency virus type 1 (HIV-1)-infected patients who started to use indinavir (800 mg three times a day) as part of their triple drug regimen were included in a study to determine the importance of low plasma concentrations of indinavir as a cause of virological treatment failure. The indinavir concentration and a number of patient characteristics at baseline were tested as risk factors for virological treatment failure (defined as a viral load above 200 copies/ml after 24 weeks of treatment) in univariate and multivariate analyses; 65 patients were included. Virological treatment failure occurred in 36.9% of the patients. Multivariate analysis showed that a low plasma concentration of indinavir (odds ratio 0.1), a high viral load at baseline (odds ratio 2.6) and pretreatment with another protease inhibitor (odds ratio 10.0) were independent factors related to virological treatment failure. Monitoring of indinavir plasma concentrations may be an important tool for the optimization of triple drug combination therapy.
Collapse
Affiliation(s)
- David M Burger
- Department of Clinical Pharmacy, University Hospital Nijmegen, Nijmegen, the Netherlands
| | | | - Patricia WH Hugen
- Department of Clinical Pharmacy, University Hospital Nijmegen, Nijmegen, the Netherlands
| | - Jan W Mulder
- Department of Internal Medicine, Slotervaart Hospital, Amsterdam, the Netherlands
| | - Pieter L Meenhorst
- Department of Internal Medicine, Slotervaart Hospital, Amsterdam, the Netherlands
| | - Peter P Koopmans
- Department of General Internal Medicine, University Hospital Nijmegen, Nijmegen, the Netherlands
| | - Kees Brinkman
- Department of General Internal Medicine, University Hospital Nijmegen, Nijmegen, the Netherlands
| | - Monique Keuter
- Department of General Internal Medicine, University Hospital Nijmegen, Nijmegen, the Netherlands
| | - Wil Dolmans
- Department of General Internal Medicine, University Hospital Nijmegen, Nijmegen, the Netherlands
| | - Yechiel A Hekster
- Department of Clinical Pharmacy, University Hospital Nijmegen, Nijmegen, the Netherlands
| |
Collapse
|
1303
|
Affiliation(s)
- C Flexner
- Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
| |
Collapse
|
1304
|
Ott DE, Hewes SM, Alvord WG, Henderson LE, Arthur LO. Inhibition of Friend virus replication by a compound that reacts with the nucleocapsid zinc finger: anti-retroviral effect demonstrated in vivo. Virology 1998; 243:283-92. [PMID: 9568028 DOI: 10.1006/viro.1998.9062] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
The zinc finger structure that is found in the nucleocapsid protein of nearly all retroviruses has been proposed as a target for antiviral therapy. Since compounds that chemically attack the cysteines of the finger have been shown to inactivate both human immunodeficiency virus type 1 (HIV-1) and murine leukemia virus (MuLV) in vitro, 14 of these compounds were tested in an MuLV-induced Friend disease model to assess their ability to inhibit retroviral replication in vivo. Of the 14 compounds tested, only Aldrithiol-2 clearly exhibited anti-retroviral activity as measured indirectly by the delay of Friend disease onset (P < 0.05). These results were confirmed by quantitative competitive polymerase chain reaction studies which monitored viral spread by measuring the level of viral DNA in the peripheral blood mononuclear cells of treated mice. Comparison of treated mice with untreated mice revealed that Aldrithiol-2 produced a greater than 2-log reduction in virus levels. These results functionally demonstrate that a zinc finger-attacking compound can inhibit viral replication in vivo. Since only 1 of the 14 compounds studied was effective, this study also shows the importance of in vivo testing of these types of antiviral compounds in an animal model. Given the strict conservation of the metal-coordinating cysteine structure within HIV-1 and MuLV zinc fingers, our results support the proposal that anti-retroviral drugs which target the nucleocapsid zinc finger may be clinically useful against HIV-1.
Collapse
Affiliation(s)
- D E Ott
- AIDS Vaccine Program, SAIC/Frederick, National Cancer Institute, Maryland 21702-1201, USA.
| | | | | | | | | |
Collapse
|
1305
|
D'Amato RM, D'Aquila RT, Wein LM. Management of Antiretroviral Therapy for HIV Infection: Modelling when to Change Therapy. Antivir Ther 1998. [DOI: 10.1177/135965359800300302] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Objective To evaluate four strategies for monitoring plasma HIV RNA levels and/or resistance genotypes to decide when to change antiretroviral therapy. The strategies include: (i) 1997 guidelines recommending a therapy switch when plasma RNA exceeds a threshold level; (ii) a viral load policy, using a fixed increase in viral load as the trigger; (iii) a genotype policy, requiring a smaller viral rebound than (ii) and detection of genotypic resistance before switching; and (iv) a proactive policy, switching drug regimens at a predetermined time if viral load has not rebounded. Design and setting A Monte Carlo simulation tracks patients’ viral loads and presence of opportunistic infection during therapy. The model uses clinical and virological data and statistical variation in patient parameters for the evaluation of therapeutic strategies. Main outcome measures: To determine which strategies minimize viral rebound detection delay while maintaining a low (prespecified) probability of switching therapy before rebound. Results 1997 Guidelines and the viral load policy create lengthy delays in detection of rebound, particularly when patients are drug-naive and the detection limit of the viral load assay is 500 copies/ml. A detection limit of 20 copies/ml decreases this delay substantially. Genotyping achieves only minor additional delay reductions. Of the strategies tested, the proactive policy leads to the shortest delays. Conclusions This model indicates that prolonged periods may be required for viral load to rebound to detectable levels following prolonged suppression. Proactive switching produces the best outcome in our model because it may reduce the duration of viral replication under pressure of a failing regimen before detection of viral rebound. This strategy should be evaluated in clinical trials.
Collapse
Affiliation(s)
- Rebecca M D'Amato
- Operations Research Center, Massachusetts Institute of Technology, Cambridge, MA 02139
| | - Richard T D'Aquila
- Infectious Disease Unit and AIDS Research Center, Massachusetts General Hospital, 149 13th Street, Charlestown, MA 02129
| | - Lawrence M Wein
- Sloan School of Management, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| |
Collapse
|
1306
|
Reiter GS. Human immunodeficiency virus (HIV) in America, 1981 to 1997: epidemiologic and therapeutic considerations. Semin Ultrasound CT MR 1998; 19:122-7. [PMID: 9567317 DOI: 10.1016/s0887-2171(98)90054-3] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
In the last 16 years, acquired immunodeficiency syndrome (AIDS) has evolved from a mysterious syndrome apparently afflicting only gay men, into a viral illness affecting every segment of society. Until the advent of combination antiretroviral therapy, HIV appeared to be universally fatal. New therapies and technologies have been developed offering normal or near-normal life spans for some people living with HIV. Coincident with the development of life-prolonging therapies has been the realization that competent HIV care requires the integration of medical care, social services, and psychological support services to promote therapeutic adherence and maximize quality of life.
Collapse
Affiliation(s)
- G S Reiter
- University of Massachusetts Medical Center Worcester, MA, USA
| |
Collapse
|
1307
|
Zennou V, Mammano F, Paulous S, Mathez D, Clavel F. Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo. J Virol 1998; 72:3300-6. [PMID: 9525657 PMCID: PMC109806 DOI: 10.1128/jvi.72.4.3300-3306.1998] [Citation(s) in RCA: 180] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
We examined the viral replicative capacity and protease-mediated processing of Gag and Gag-Pol precursors of human immunodeficiency virus (HIV) variants selected for resistance to protease inhibitors. We compared recombinant viruses carrying plasma HIV RNA protease sequences obtained from five patients before protease inhibitor therapy and after virus escape from the treatment. Paired pretherapy-postresistance reconstructed viruses were evaluated for HIV infectivity in a quantitative single-cycle titration assay and in a lymphoid cell propagation assay. We found that all reconstructed resistant viruses had a reproducible decrease in their replicative capacity relative to their parental pretherapy counterparts. The extent of this loss of infectivity was pronounced for some viruses and more limited for others, irrespective of the inhibitor used and of the level of resistance. In resistant viruses, the efficiency of Gag and Gag-Pol precursor cleavage by the protease was impaired to different extents, as shown by the accumulation of several cleavage intermediates in purified particle preparations. We conclude that protease inhibitor-resistant HIV variants selected during therapy have an impaired replicative capacity related to multiple defects in the processing of Gag and Gag-Pol polyprotein precursors by the protease.
Collapse
MESH Headings
- Cell Line, Transformed
- Cloning, Molecular
- Drug Resistance, Microbial
- Drug Resistance, Multiple
- Fusion Proteins, gag-pol/drug effects
- Fusion Proteins, gag-pol/metabolism
- Gene Products, gag/drug effects
- Gene Products, gag/metabolism
- Genetic Variation
- HIV Protease Inhibitors/pharmacology
- HIV-1/drug effects
- HIV-1/genetics
- HIV-1/metabolism
- HIV-1/physiology
- HeLa Cells
- Humans
- Protein Processing, Post-Translational/drug effects
- Proteins/metabolism
- Recombination, Genetic
- Tumor Cells, Cultured
- Virus Replication
Collapse
Affiliation(s)
- V Zennou
- Unité d'Oncologie Virale, Département Sida et Rétrovirus, Institut Pasteur, Paris, France
| | | | | | | | | |
Collapse
|
1308
|
Rothen M, Bisset LR, Joller-Jemelka HI, Grob P, Lüthy R, Opravil M. Improvement in Immune Function due to Treatment with Indinavir despite Severe Immune Deficiency. Antivir Ther 1998. [DOI: 10.1177/135965359800300308] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
To study the virological, immunological and clinical effects of the protease inhibitor indinavir in human immunodeficiency virus (HlV)-infected patients with CD4 counts <50 cells/mm3, indinavir was added to prior treatment with nucleoside analogues in a prospective open-label study in 23 HIV-infected patients with median CD4 count of 10 cells/mm3 and median serum HIV-1 RNA load of 27508 copies/ml. Addition of indinavir induced a decrease in HIV-1 RNA levels to <400 copies/ml in 15 patients that was maintained until week 36 of the study in 8 (35%) patients. The median increase in CD4 cell counts was 92 cells/mm3 (range 55–258 cells/mm3) and in CD8 counts was 245 cells/mm3 (range 51–1552 cells/mm3) at week 30. The treatment induced a significant CD8 T cell expansion, consisting in the first 6 weeks of predominantly memory CD45RO+ cells and followed by expansion of naive cells from week 12 on, and a significant decrease in the proportion of activated CD8/CD38 cells. In addition, significant increases in T cell proliferation following stimulation with phytohaemagglutinin and significant decreases in the rates of spontaneous apoptosis of CD4+ and CD8+ T cells were observed. In conclusion, the addition of indinavir induced restoration of both memory and naive CD8 T cells. Corresponding evidence of improving T cell function, as assessed by enhanced lymphoproliferative capacity and diminished propensity to undergo apoptosis, provides evidence for treatment-induced regeneration of immune function even in patients with severe immunodeficiency.
Collapse
Affiliation(s)
| | - Leslie R Bisset
- Division of Clinical Immunology, Department of Medicine, University Hospital Zurich, Switzerland
| | - Helene I Joller-Jemelka
- Division of Clinical Immunology, Department of Medicine, University Hospital Zurich, Switzerland
| | - Peter Grob
- Division of Clinical Immunology, Department of Medicine, University Hospital Zurich, Switzerland
| | - Ruedi Lüthy
- Division of Infectious Diseases and Hospital Epidemiology
| | - Milos Opravil
- Division of Infectious Diseases and Hospital Epidemiology
| |
Collapse
|
1309
|
Opravil M, Hill AM, DeMasi R, Dawson D. Prediction of HIV-1 RNA Suppression and its Durability during Treatment with Zidovudine/Lamivudine. Antivir Ther 1998. [DOI: 10.1177/135965359800300307] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
To predict the probability of long-term viral suppression during treatment with zidovudine and lamivudine, human immunodeficiency virus type 1 (HIV-1) RNA values were retrospectively pooled for 1083 patients from six randomized, double-blind clinical trials. All analyses of HIV-1 RNA were obtained using the Roche Amplicor assay or its earlier prototype. Time to loss of response was evaluated by Kaplan-Meier analysis; Cox proportional hazards models were used to assess the influence of baseline variables. Among 523 patients with ≤6 months of prior zidovudine treatment, the probability of HIV-1 RNA suppression below 400 copies/ml at 48 weeks was 71% in those with baseline HIV-1 RNA <5000 copies/ml, but only 14% in those with HIV-1 RNA between 50000 and 200000 copies/ml. Among 560 patients with >6 months of prior zidovudine treatment, the rates of sustained viral suppression were lower, but also significantly associated with the baseline HIV-1 RNA. Multivariate analyses showed no independent effect of CD4 cell count, age, sex, race, or CDC disease stage on the probability of sustained HIV-1 RNA suppression. When patients with ≤6 months of prior therapy were stratified based on the magnitude of HIV-1 RNA nadir achieved during treatment, those who reached a nadir of <400 copies/ml retained this response for significantly longer time periods than the ones who only achieved partial viral suppression. In conclusion, baseline HIV-1 RNA levels and the duration of prior zidovudine therapy strongly predict the antiretroviral efficacy of zidovudine/lamivudine. The baseline parameters should influence the choice of the antiretroviral regimen.
Collapse
Affiliation(s)
- Milos Opravil
- Division of Infectious Diseases and Hospital Epidemiology, University Hospital, Zurich, Switzerland
| | - Andrew M Hill
- Antiviral Clinical Research, Glaxo Wellcome, Greenford, Middlesex, UK
| | - Ralph DeMasi
- Glaxo Wellcome, Research Triangle Park, North Carolina, USA
| | - Debra Dawson
- Glaxo Wellcome, Research Triangle Park, North Carolina, USA
| |
Collapse
|
1310
|
Strategies of Antiretroviral Therapy in Adults. Oncologist 1998. [DOI: 10.1634/theoncologist.3-2-111] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
1311
|
Krischer J, Rutschmann O, Hirschel B, Vollenweider-Roten S, Saurat JH, Pechère M. Regression of Kaposi's sarcoma during therapy with HIV-1 protease inhibitors: a prospective pilot study. J Am Acad Dermatol 1998; 38:594-8. [PMID: 9555800 DOI: 10.1016/s0190-9622(98)70124-0] [Citation(s) in RCA: 48] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
BACKGROUND Early studies using HIV protease inhibitors (PI) showed regression of Kaposi's sarcoma (KS) lesions in some patients. OBJECTIVE Our purpose was to determine prospectively the influence of PI on HIV-related KS. METHODS KS lesions of nine patients with progressive cutaneous disease were prospectively evaluated clinically and by means of epiluminescence microscopy before and during PI therapy. HIV viremia and CD4 cell count were measured in parallel. RESULTS All patients experienced reduction or initial stabilization of KS lesions during the first 4 to 8 weeks of HIV-1 PI therapy. After a median follow-up of 7 months and according to AIDS Clinical Trials Groups criteria, six patients had a partial response, two showed stable disease, and in one noncompliant patient KS progressed, requiring chemotherapy. With epiluminescence microscopy, a reduction in skin surface alterations, lesional size, and color intensity was demonstrated in six of nine patients. PI induced a median decrease in viremia of 1.66 log and a median increase in the CD4 count of 49 cells/mm3. CONCLUSION In this series, HIV PI therapy reduced or stabilized KS. The efficacy of HIV-1 PI in KS may result from the improvement in cellular immunity. These results suggest the use of PI in AIDS-related KS regardless of the level of CD4 lymphocyte count and HIV viremia.
Collapse
Affiliation(s)
- J Krischer
- Department of Dermatology, University Hospital Geneva, Switzerland
| | | | | | | | | | | |
Collapse
|
1312
|
Affiliation(s)
- D M Coen
- Dept of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA.
| |
Collapse
|
1313
|
Kempf DJ, Rode RA, Xu Y, Sun E, Heath-Chiozzi ME, Valdes J, Japour AJ, Danner S, Boucher C, Molla A, Leonard JM. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS 1998; 12:F9-14. [PMID: 9543434 DOI: 10.1097/00002030-199805000-00001] [Citation(s) in RCA: 169] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
OBJECTIVE To determine markers that are associated with the durability of virologic response to therapy with HIV protease inhibitors in HIV-infected individuals. DESIGN This study encompassed two retrospective analyses of the duration of virologic response to protease inhibitor therapy. The first analysis included 29 patients receiving either monotherapy or combination therapy with the protease inhibitor ritonavir whose plasma HIV RNA levels rebounded from the point of greatest decline with mutations associated with resistance to ritonavir. The second analysis included a cohort of 102 patients who initially responded to randomized treatment with either monotherapy with ritonavir or combination therapy with ritonavir and zidovudine. METHODS Durability of response was defined as the time from the initiation of therapy to the point at which plasma HIV RNA displayed a sustained increase of at least 0.6 log10 copies/ml from the nadir value. In the first analysis, durability of response was analyzed with respect to baseline HIV RNA, HIV RNA at the nadir, and the drop in HIV RNA from baseline to the nadir. In the second analysis, time to rebound was examined using Kaplan-Meier analysis, stratifying by either baseline HIV RNA or HIV RNA at the nadir. RESULTS In both analyses, the durability of response was not highly associated with either baseline RNA or the magnitude of RNA decline from baseline. Instead, a strong relationship was observed between the durability of response and the nadir plasma HIV-1 RNA value (P < 0.01). The nadir in viral load was generally reached after 12 weeks of randomized therapy. CONCLUSIONS Viral RNA determinations at intermediate timepoints may be prognostic of impending virologic failure of protease inhibitor therapy. Therapeutic strategies that allow intensification of initial antiretroviral regimens in the subset of patients with incomplete virological response before the emergence of high level resistance should be investigated.
Collapse
Affiliation(s)
- D J Kempf
- Department of Infectious Diseases Research, Abbott Laboratories, Abbott Park, Illinois 60064-3500, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
1314
|
Günthard HF, Wong JK, Ignacio CC, Guatelli JC, Riggs NL, Havlir DV, Richman DD. Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. J Virol 1998; 72:2422-8. [PMID: 9499103 PMCID: PMC109542 DOI: 10.1128/jvi.72.3.2422-2428.1998] [Citation(s) in RCA: 161] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/1997] [Accepted: 12/15/1997] [Indexed: 02/06/2023] Open
Abstract
Potent antiretroviral therapy can reduce human immunodeficiency virus (HIV) in plasma to levels below the limit of detection for up to 2 years, but the extent to which viral replication is suppressed is unknown. To search for ongoing viral replication in 10 patients on combination antiretroviral therapy for up to 1 year, the emergence of genotypic drug resistance across different compartments was studied and correlated with plasma viral RNA levels. In addition, lymph node (LN) mononuclear cells were assayed for the presence of multiply spliced RNA. Population sequencing of HIV-1 pol was done on plasma RNA, peripheral blood mononuclear cell (PBMC) RNA, PBMC DNA, LN RNA, LN DNA, and RNA from virus isolated from PBMCs or LNs. A special effort was made to obtain sequences from patients with undetectable plasma RNA, emphasizing the rapidly emerging lamivudine-associated M184V mutation. Furthermore, concordance of drug resistance mutations across compartments was investigated. No evidence for viral replication was found in patients with plasma HIV RNA levels of <20 copies/ml. In contrast, evolving genotypic drug resistance or the presence of multiply spliced RNA provided evidence for low-level replication in subjects with plasma HIV RNA levels between 20 and 400 copies/ml. All patients failing therapy showed multiple drug resistance mutations in different compartments, and multiply spliced RNA was present upon examination. Concordance of nucleotide sequences from different tissue compartments obtained concurrently from individual patients was high: 98% in the protease and 94% in the reverse transcriptase regions. These findings argue that HIV replication differs significantly between patients on potent antiretroviral therapy with low but detectable viral loads and those with undetectable viral loads.
Collapse
Affiliation(s)
- H F Günthard
- Department of Pathology, School of Medicine, University of California San Diego, La Jolla 92093-0679, USA.
| | | | | | | | | | | | | |
Collapse
|
1315
|
Barry M, Mulcahy F, Back DJ. Antiretroviral therapy for patients with HIV disease. Br J Clin Pharmacol 1998; 45:221-8. [PMID: 9517365 PMCID: PMC1873374 DOI: 10.1046/j.1365-2125.1998.00673.x] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/1997] [Accepted: 10/30/1997] [Indexed: 02/06/2023] Open
Affiliation(s)
- M Barry
- Department of Pharmacology and Therapeutics, University of Liverpool, UK
| | | | | |
Collapse
|
1316
|
Affiliation(s)
- A Pozniak
- Department of HIV and Genitourinary Medicine, King's College Hospital, London, UK
| |
Collapse
|
1317
|
Hogg RS, Rhone SA, Yip B, Sherlock C, Conway B, Schechter MT, O'Shaughnessy MV, Montaner JS. Antiviral effect of double and triple drug combinations amongst HIV-infected adults: lessons from the implementation of viral load-driven antiretroviral therapy. AIDS 1998; 12:279-84. [PMID: 9517990 DOI: 10.1097/00002030-199803000-00005] [Citation(s) in RCA: 68] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
OBJECTIVE To study the antiviral effect and predictors of response to two- and three-drug regimens amongst antiretroviral-naive individuals using an intent-to-treat analysis. MAIN OUTCOME MEASURE Suppression of plasma viral load to < 500 copies/ml. PATIENTS A total of 420 (264 double drug, 156 triple drug) individuals in a province-wide treatment programme were studied. RESULTS A decrease in plasma viral load to < 500 copies/ml was documented in 197 (47%) subjects. This was independently associated with a lower baseline plasma viral load (odds ratio, 3.67; 95% confidence interval, 2.13-6.30) and initiation onto a three-drug regimen (odds ratio, 3.86; 95% confidence interval, 2.24-6.66). Median plasma viral load failed to reach < 500 copies/ml and in fact rebounded in the two-drug group. In contrast, 91 (58%) subjects receiving three drugs reached < 500 copies/ml during the study period. CONCLUSION These results support the use of powerful triple drug regimens as initial therapy in HIV-infected individuals.
Collapse
Affiliation(s)
- R S Hogg
- British Columbia Centre for Excellence in HIV/AIDS, St Paul's Hospital, University of British Columbia, Vancouver, Canada.
| | | | | | | | | | | | | | | |
Collapse
|
1318
|
Andiman WA. Medical management of the pregnant woman infected with human immunodeficiency virus type 1 and her child. Semin Perinatol 1998; 22:72-86. [PMID: 9523401 DOI: 10.1016/s0146-0005(98)80009-8] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Heterosexual contact and intravenous drug use continue to result in new cases of human immunodeficiency virus type 1 (HIV-1) infection among adolescents and women of childbearing age. In North American and European surveys, 0.1% to 0.3% of childbearing women are infected with HIV; rates are 10 to 20 times higher in some inner-city areas. Timely, comprehensive, and well-coordinated care of the pregnant HIV-infected mother offers a unique opportunity to significantly influence two lives simultaneously. The mother can be offered therapeutic and prophylactic agents to treat her own infection, including antiretroviral therapy, which has been shown to markedly reduce the risk of vertical HIV-1 transmission. Recent advances in diagnostic virology now make it possible to definitively identify by 3 to 4 months of age those infants who are infected with HIV. Infants infected with HIV can be offered effective prophylaxis against Pneumocystis carinii pneumonia, which has dramatically reduced the incidence of this once common infection. Infected infants also should be monitored closely to institute antiretroviral therapy, and to diagnose and treat opportunistic and intercurrent infections and other acquired immunodeficiency syndrome-defining illnesses in a timely way.
Collapse
Affiliation(s)
- W A Andiman
- Department of Pediatrics, Yale University School of Medicine, New Haven, CT 06520, USA
| |
Collapse
|
1319
|
Yeh KC, Deutsch PJ, Haddix H, Hesney M, Hoagland V, Ju WD, Justice SJ, Osborne B, Sterrett AT, Stone JA, Woolf E, Waldman S. Single-dose pharmacokinetics of indinavir and the effect of food. Antimicrob Agents Chemother 1998; 42:332-8. [PMID: 9527781 PMCID: PMC105409 DOI: 10.1128/aac.42.2.332] [Citation(s) in RCA: 57] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
Indinavir sulfate is a human immunodeficiency virus type 1 (HIV-1) protease inhibitor indicated for treatment of HIV infection and AIDS in adults. The purpose of this report is to summarize single-dose studies which characterized the pharmacokinetics of the drug and the effect of food in healthy volunteers. Indinavir concentrations in plasma and urine were obtained by high-pressure liquid chromatography and UV detection assay methods. The results indicate that indinavir was rapidly absorbed in the fasting state, with the time to the maximum concentration in plasma occurring at approximately 0.8 h for all doses studied. Over the 40- to 1,000-mg dose range studied, concentrations in plasma and urinary excretion of unchanged drug increased greater than dose proportionally. The nonlinear pharmacokinetics were attributed to the dose-dependent oxidative metabolism of first-pass metabolism as well as to metabolism in the systemic circulation. Renal clearance slightly exceeded the glomerular filtration rate, suggesting a net tubular secretion component. At high concentrations in plasma, tubular secretion appeared to be lowered because there was a trend for a decreased renal clearance. Administration of 400 mg of indinavir sulfate following a high-fat breakfast resulted in a blunted and decreased absorption (areas under the concentration-time curves [AUCs], 6.86 microM.h in the fasted state versus 1.54 microM.h in the fed state; n = 10). However, two types of low-fat meals were found to have no significant effect on the absorption of 800 mg of indinavir sulfate (AUCs, 23.15 microM.h in the fasted state versus 22.71 and 21.36 microM.h, respectively, in the fed state; n = 11). Immediately following dosing, the concentrations of indinavir in urine often exceeded its intrinsic solubility. To reduce the risk of nephrolithiasis, it is recommended that indinavir sulfate be administered with water.
Collapse
Affiliation(s)
- K C Yeh
- Merck Research Laboratories, West Point, Pennsylvania 19486, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
1320
|
Boyer PL, Gao HQ, Hughes SH. A mutation at position 190 of human immunodeficiency virus type 1 reverse transcriptase interacts with mutations at positions 74 and 75 via the template primer. Antimicrob Agents Chemother 1998; 42:447-52. [PMID: 9527805 PMCID: PMC105433 DOI: 10.1128/aac.42.2.447] [Citation(s) in RCA: 55] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
We have analyzed amino acid substitutions at position G190 in the reverse transcriptase (RT) of human immunodeficiency virus type 1 (HIV-1). The mutation G190E, which is responsible for resistance to certain nonnucleoside inhibitors, results in RT that has significantly less polymerase activity and that is less processive than wild-type RT. Its kinetic profile with respect to dGTP and poly(rC).oligo(dG) is significantly altered compared to that of wild-type RT. The combination of either of the mutations L74V or V75I with the G190E mutation appears to be compensatory and mitigates many of the deleterious effects of the G190E mutation.
Collapse
Affiliation(s)
- P L Boyer
- ABL-Basic Research Program, NCI-Frederick Cancer Research and Development Center, Maryland 21702-1201, USA
| | | | | |
Collapse
|
1321
|
Notermans DW, Jurriaans S, de Wolf F, Foudraine NA, de Jong JJ, Cavert W, Schuwirth CM, Kauffmann RH, Meenhorst PL, McDade H, Goodwin C, Leonard JM, Goudsmit J, Danner SA. Decrease of HIV-1 RNA levels in lymphoid tissue and peripheral blood during treatment with ritonavir, lamivudine and zidovudine. Ritonavir/3TC/ZDV Study Group. AIDS 1998; 12:167-73. [PMID: 9468365 DOI: 10.1097/00002030-199802000-00006] [Citation(s) in RCA: 127] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
OBJECTIVES Triple combination treatment of HIV-1 infection using two reverse transcriptase inhibitors and a protease inhibitor can result in significant and sustained decreases in the quantity of viral RNA in peripheral blood. Lymphoid tissue, however, constitutes the major reservoir of HIV in infected patients. Study of the viral burden in these tissues has provided additional insight in the efficacy of antiretroviral treatment. DESIGN Patients were randomized into two groups in order to study differences in the development of resistance to reverse transcriptase inhibitors. Group I started treatment with all three drugs simultaneously. Group II started with ritonavir monotherapy, aiming at initial reduction in virus production before the addition of lamivudine and zidovudine 3 weeks later. METHODS Changes in the amount of HIV in plasma and tonsillar lymphoid tissue during 24 weeks of treatment with ritonavir, lamivudine and zidovudine were studied by reverse transcriptase polymerase chain reaction. RESULTS Thirty-three antiretroviral-naive HIV-infected patients were included for analysis. After 24 weeks, median CD4+ cell count increased by 152 x 10(6)/l and median plasma viral RNA levels decreased by at least 2.87 log10 copies/ml. In 88% of the patients remaining on treatment, plasma RNA levels were below the quantification limit of the assay used (mean, 2.4 log10 copies/ml). The lymphoid tissue viral burden, ranging from 9.16 to 8.52 log10 copies/g at baseline, was markedly reduced with at least 2.1 log10 copies/g by week 24 in the five patients analysed. Eight patients (24%) withdrew because of side-effects. In one patient in group II, ritonavir and lamivudine resistance-associated mutations developed. CONCLUSIONS Treatment with this triple antiretroviral drug combination produced a durable and strong decrease of HIV-1 RNA burden in both plasma and lymphoid tissue.
Collapse
Affiliation(s)
- D W Notermans
- Division of Infectious Diseases, Tropical Medicine and AIDS and National AIDS Therapy Evaluation Centre, Amsterdam, The Netherlands
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
1322
|
Lange JMA, Richman DD. The Limitations of Simplicity. Antivir Ther 1998. [DOI: 10.1177/135965359800300104] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
1323
|
Duffy B, Schwietert C, France A, Mann N, Culbertson K, Harmon B, McCue JP. Transition metals as protease inhibitors. Biol Trace Elem Res 1998; 64:197-213. [PMID: 9845474 DOI: 10.1007/bf02783336] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
An alternative approach to the development of clinically useful protease inhibitors was investigated. The approach utilized coordination chemistry of transition metal ions rather than substrate analogs to block active sites of these enzymes. In the case of serine proteases it was found that aqueous Ti(IV) is a potent inhibitor of the trypsin subclass, but not the chymotrypsin subclass. The direct binding of Ti(IV) to trypsin was made possible by the presence of a free carboxyl group at the bottom of the substrate binding pocket of the enzyme, and the five-coordinate geometry of TiO(SO4)(H2O). Although initial binding of Ti(IV) was reversible, it was followed in time by irreversible inhibition. Direct binding of octahedral or tetrahedral metal ion complexes was prevented by the inability of the enzyme active sites to promote formation of a five-coordinate transition state of the metal ion required for reaction. These studies demonstrate the ability of direct metal ion binding as a way to enhance blocking of enzyme active sites as compared with that of traditional organic inhibitors. Application of these findings was investigated by measuring the affect Ti(IV) had on growth of Escherichia coli, Salmonella typhimurium, and Pseudomonas aeruginosa. Five-coordinate titanyl sulfate completely inhibited the growth of these organisms. This suggests that five-coordinate titanyl sulfate, which is easier and less expensive to manufacture than conventional antibiotics, may be useful in controlling endemic infections of E. coli and S. typhimurium.
Collapse
Affiliation(s)
- B Duffy
- The Gibson Institute for Medical Research, Santa Rosa, CA, USA
| | | | | | | | | | | | | |
Collapse
|
1324
|
Moyle GJ, Gazzard BG. Lamivudine in the Management of Adults with Human Immunodeficiency Virus Type 1 Infection. Antivir Ther 1998. [DOI: 10.1177/135965359800300106] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Lamivudine is a nucleoside analogue reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1), HIV-2 and hepatitis B virus which demonstrates in vitro activity with a high therapeutic index in a range of T lymphocyte and haematopoietic precursor cell lines. It is synergistic in vitro with a range of other antiretrovirals including other nucleoside analogues, non-nucleoside reverse transcriptase inhibitors and protease inhibitors, in two- and three-way combinations and is active against virus resistant to zidovudine and most other antiretrovirals. It exhibits excellent oral bioavailability and penetrates the CSF. In clinical use, lamivudine exhibits limited antiretroviral activity as a monotherapy, but in two-and three-drug combinations with other antiretrovirals it provides potent antiretroviral activity and significantly delays clinical events. Adverse events appear infrequent and are generally mild and self-limiting. Resistance to lamivudine develops rapidly in vitro and in vivo but may delay the development of zidovudine resistance. Dual zidovudine-lamivudine resistance is well documented both in vitro and in vivo although the mutation at codon 184 of reverse transcriptase characteristic of lamivudine resistance may, in some cases, transiently ‘reverse’ zidovudine resistance mediated through codons 215 and 41. Owing to concerns regarding selection of virus with cross-resistance to other nucleoside analogues (ddl, ddC and possibly abacavir), whether to use lamivudine in initial or second-line regimens is currently under debate.
Collapse
Affiliation(s)
- Graeme J Moyle
- Kobler Clinic, Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9TH, UK
| | - Brian G Gazzard
- Kobler Clinic, Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9TH, UK
| |
Collapse
|
1325
|
Mas A, Soriano V, Gómez-Cano M, Rodríguez-Rosado R, Pérez-Olmeda M, González-Lahoz J. The Ultrasensitive NASBA Assay for Quantifying HIV-1 Viral Load. Antivir Ther 1998. [DOI: 10.1177/135965359800300105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The maintenance of undetectable levels of human immunodeficiency virus (HIV) viraemia seems to assure sustained benefit of antiretroviral therapy, since ongoing virus replication under drug pressure offers the opportunity for resistant variants to emerge and replicate. The early recognition of even low levels of virus replication should be helpful, allowing clinicians to consider switching therapy before accumulation of drug-resistant mutations has occurred. In this context, ultrasensitive assays could be very helpful. The new nucleic acid sequence-based assay (NASBA) (Nuclisens, Organon-Teknika), which has a limit of detection of 20 HIV RNA copies/ml, was tested in clinical specimens from 42 HIV-infected patients receiving different antiretroviral treatments and having undetectable levels of plasma viraemia (<500 copies/ml) using another less sensitive quantification method. Overall, 21 (50%) samples were positive and yielded quantitative values using Nuclisens. Since complete suppression of virus replication may be necessary to avoid the development of drug-resistant mutants, the introduction of ultrasensitive methods for monitoring response to treatment should be recommended when eradicative strategies are pursued.
Collapse
Affiliation(s)
- Antonio Mas
- Service of Infectious Diseases, Instituto de Salud Carlos III, Madrid, Spain
| | - Vicenç Soriano
- Service of Infectious Diseases, Instituto de Salud Carlos III, Madrid, Spain
| | - María Gómez-Cano
- Service of Infectious Diseases, Instituto de Salud Carlos III, Madrid, Spain
| | | | - Mayte Pérez-Olmeda
- Service of Infectious Diseases, Instituto de Salud Carlos III, Madrid, Spain
| | - Juan González-Lahoz
- Service of Infectious Diseases, Instituto de Salud Carlos III, Madrid, Spain
| |
Collapse
|
1326
|
McDougall B, King PJ, Wu BW, Hostomsky Z, Reinecke MG, Robinson WE. Dicaffeoylquinic and dicaffeoyltartaric acids are selective inhibitors of human immunodeficiency virus type 1 integrase. Antimicrob Agents Chemother 1998; 42:140-6. [PMID: 9449274 PMCID: PMC105469 DOI: 10.1128/aac.42.1.140] [Citation(s) in RCA: 167] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
Current pharmacological agents for human immunodeficiency virus (HIV) infection include drugs targeted against HIV reverse transcriptase and HIV protease. An understudied therapeutic target is HIV integrase, an essential enzyme that mediates integration of the HIV genome into the host chromosome. The dicaffeoylquinic acids (DCQAs) and the dicaffeoyltartaric acids (DCTAs) have potent activity against HIV integrase in vitro and prevent HIV replication in tissue culture. However, their specificity against HIV integrase in cell culture has been questioned. Thus, the ability of the DCQAs and DCTAs to inhibit binding of HIV type 1 (HIV-1) gp120 to CD4 and their activities against HIV-1 reverse transcriptase and HIV RNase H were studied. The DCQAs and DCTAs inhibited HIV-1 integrase at concentrations between 150 and 840 nM. They inhibited HIV replication at concentrations between 2 and 12 microM. Their activity against reverse transcriptase ranged from 7 microM to greater than 100 microM. Concentrations that inhibited gp120 binding to CD4 exceeded 80 microM. None of the compounds blocked HIV-1 RNase H by 50% at concentrations exceeding 80 microM. Furthermore, when the effects of the DCTAs on reverse transcription in acutely infected cells were measured, they were found to have no activity. Therefore, the DCQAs and DCTAs exhibit > 10- to > 100-fold specificity for HIV integrase, and their activity against integrase in biochemical assays is consistent with their observed anti-HIV activity in tissue culture. Thus, the DCQAs and DCTAs are a potentially important class of HIV inhibitors that act at a site distinct from that of current HIV therapeutic agents.
Collapse
Affiliation(s)
- B McDougall
- Department of Pathology, University of California, Irvine 92697-4800, USA
| | | | | | | | | | | |
Collapse
|
1327
|
Affiliation(s)
- P A Volberding
- UCSF AIDS program, San Francisco General Hospital 94110, USA
| |
Collapse
|
1328
|
|
1329
|
Endres MJ, Jaffer S, Haggarty B, Turner JD, Doranz BJ, O'Brien PJ, Kolson DL, Hoxie JA. Targeting of HIV- and SIV-infected cells by CD4-chemokine receptor pseudotypes. Science 1997; 278:1462-4. [PMID: 9367958 DOI: 10.1126/science.278.5342.1462] [Citation(s) in RCA: 52] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Retroviral vectors containing CD4 and an appropriate chemokine receptor were evaluated for the ability to transduce cells infected with human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV). These CD4-chemokine receptor pseudotypes were able to target HIV- and SIV-infected cell lines and monocyte-derived macrophages in a manner that corresponded to the specificity of the viral envelope glycoprotein for its CD4-chemokine receptor complex. This approach could offer a way to deliver antiviral genes directly to HIV-infected cells in vivo and could provide an additional treatment strategy in conjunction with existing antiviral therapies.
Collapse
Affiliation(s)
- M J Endres
- Department of Medicine, Hematology-Oncology Division, University of Pennsylvania, Philadelphia, PA 19104, USA.
| | | | | | | | | | | | | | | |
Collapse
|
1330
|
Wong JK, Hezareh M, Günthard HF, Havlir DV, Ignacio CC, Spina CA, Richman DD. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997; 278:1291-5. [PMID: 9360926 DOI: 10.1126/science.278.5341.1291] [Citation(s) in RCA: 1612] [Impact Index Per Article: 59.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
In evaluating current combination drug regimens for treatment of human immunodeficiency virus (HIV) disease, it is important to determine the existence of viral reservoirs. After depletion of CD8 cells from the peripheral blood mononuclear cells (PBMCs) of both patients and normal donors, activation of patient CD4 lymphocytes with immobilized antibodies to CD3 and CD28 enabled the isolation of virus from PBMCs of six patients despite the suppression of their plasma HIV RNA to fewer than 50 copies per milliliter for up to 2 years. Partial sequencing of HIV pol revealed no new drug resistance mutations or discernible evolution, providing evidence for viral latency rather than drug failure.
Collapse
Affiliation(s)
- J K Wong
- Department of Medicine, University of California, San Diego, School of Medicine, 9500 Gilman Drive, La Jolla, CA 92093, USA
| | | | | | | | | | | | | |
Collapse
|
1331
|
Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, Quinn TC, Chadwick K, Margolick J, Brookmeyer R, Gallant J, Markowitz M, Ho DD, Richman DD, Siliciano RF. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278:1295-300. [PMID: 9360927 DOI: 10.1126/science.278.5341.1295] [Citation(s) in RCA: 2275] [Impact Index Per Article: 84.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
The hypothesis that quiescent CD4+ T lymphocytes carrying proviral DNA provide a reservoir for human immunodeficiency virus-type 1 (HIV-1) in patients on highly active antiretroviral therapy (HAART) was examined. In a study of 22 patients successfully treated with HAART for up to 30 months, replication-competent virus was routinely recovered from resting CD4+ T lymphocytes. The frequency of resting CD4+ T cells harboring latent HIV-1 was low, 0.2 to 16.4 per 10(6) cells, and, in cross-sectional analysis, did not decrease with increasing time on therapy. The recovered viruses generally did not show mutations associated with resistance to the relevant antiretroviral drugs. This reservoir of nonevolving latent virus in resting CD4+ T cells should be considered in deciding whether to terminate treatment in patients who respond to HAART.
Collapse
Affiliation(s)
- D Finzi
- Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
1332
|
Wong JK, Günthard HF, Havlir DV, Zhang ZQ, Haase AT, Ignacio CC, Kwok S, Emini E, Richman DD. Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure. Proc Natl Acad Sci U S A 1997; 94:12574-9. [PMID: 9356491 PMCID: PMC25043 DOI: 10.1073/pnas.94.23.12574] [Citation(s) in RCA: 190] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
Potent antiretroviral therapy can reduce plasma HIV RNA levels below the threshold of detection for periods of a year or more. The magnitude of HIV RNA reduction in the lymphoid tissue in patients with suppression of HIV RNA levels in plasma beyond 6 months has not been determined. We evaluated levels of HIV RNA and DNA and characterized resistance mutations in blood and inguinal lymph node biopsies obtained from 10 HIV-infected subjects who received 36-52 weeks of indinavir (IDV)/zidovudine (ZDV)/lamivudine (3TC), IDV, or ZDV/3TC. After 1 year of therapy, viral RNA levels in LN of individuals remained detectable but were log10 = 4 lower than in subjects on the triple drug regimen with interruption of therapy or in those treated with ZDV/3TC alone, who had viral loads in their lymph nodes indistinguishable from those expected for untreated patients. In all cases viral DNA remained detectable in lymph nodes and peripheral blood mononuclear cells (PBMC). When plasma virus suppression was incomplete, lymph node and PBMC cultures were positive and drug resistance developed. These studies indicate that pronounced and sustained suppression of plasma viremia by a potent antiretroviral combination is associated with low HIV RNA levels in the lymph nodes 1 year after treatment. Conversely, the persistence of even modest levels of plasma virus after 1 year of treatment reflects ongoing viral replication, the emergence of drug resistance, and the maintenance of high burdens of virus in the lymph nodes.
Collapse
Affiliation(s)
- J K Wong
- Department of Medicine, University of California at San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
1333
|
Hogg RS, Anis A, Weber AE, O'Shaughnessy MV, Schechter MT. Triple-combination antiretroviral therapy in sub-Saharan Africa. Lancet 1997; 350:1406. [PMID: 9365484 DOI: 10.1016/s0140-6736(05)65188-4] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
|
1334
|
Doranz BJ, Grovit-Ferbas K, Sharron MP, Mao SH, Goetz MB, Daar ES, Doms RW, O'Brien WA. A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor. J Exp Med 1997; 186:1395-400. [PMID: 9334380 PMCID: PMC2199097 DOI: 10.1084/jem.186.8.1395] [Citation(s) in RCA: 241] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/1997] [Revised: 08/05/1997] [Indexed: 02/05/2023] Open
Abstract
The chemokine receptor CXCR4 is the major coreceptor used for cellular entry by T cell- tropic human immunodeficiency virus (HIV)-1 strains, whereas CCR5 is used by macrophage (M)-tropic strains. Here we show that a small-molecule inhibitor, ALX40-4C, inhibits HIV-1 envelope (Env)-mediated membrane fusion and viral entry directly at the level of coreceptor use. ALX40-4C inhibited HIV-1 use of the coreceptor CXCR4 by T- and dual-tropic HIV-1 strains, whereas use of CCR5 by M- and dual-tropic strains was not inhibited. Dual-tropic viruses capable of using both CXCR4 and CCR5 were inhibited by ALX40-4C only when cells expressed CXCR4 alone. ALX40-4C blocked stromal-derived factor (SDF)-1alpha-mediated activation of CXCR4 and binding of the monoclonal antibody 12G5 to cells expressing CXCR4. Overlap of the ALX40-4C binding site with that of 12G5 and SDF implicates direct blocking of Env interactions, rather than downregulation of receptor, as the mechanism of inhibition. Thus, ALX40-4C represents a small-molecule inhibitor of HIV-1 infection that acts directly against a chemokine receptor at the level of Env-mediated membrane fusion.
Collapse
Affiliation(s)
- B J Doranz
- Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia 19104, USA
| | | | | | | | | | | | | | | |
Collapse
|
1335
|
|
1336
|
Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, Eron JJ, Feinberg JE, Balfour HH, Deyton LR, Chodakewitz JA, Fischl MA. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 337:725-33. [PMID: 9287227 DOI: 10.1056/nejm199709113371101] [Citation(s) in RCA: 1847] [Impact Index Per Article: 68.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
BACKGROUND The efficacy and safety of adding a protease inhibitor to two nucleoside analogues to treat human immunodeficiency virus type 1 (HIV-1) infection are not clear. We compared treatment with the protease inhibitor indinavir in addition to zidovudine and lamivudine with treatment with the two nucleosides alone in HIV-infected adults previously treated with zidovudine. METHODS A total of 1156 patients not previously treated with lamivudine or protease inhibitors were stratified according to CD4 cell count (50 or fewer vs. 51 to 200 cells per cubic millimeter) and randomly assigned to one of two daily regimens: 600 mg of zidovudine (or stavudine) and 300 mg of lamivudine, or that regimen with 2400 mg of indinavir. The primary end point was the time to the development of the acquired immunodeficiency syndrome (AIDS) or death. RESULTS The proportion of patients whose disease progressed to AIDS or death was lower with indinavir, zidovudine, and lamivudine (6 percent) than with zidovudine and lamivudine alone (11 percent; estimated hazard ratio, 0.50; 95 percent confidence interval, 0.33 to 0.76; P=0.001). Mortality in the two groups was 1.4 percent and 3.1 percent, respectively (estimated hazard ratio, 0.43; 95 percent confidence interval, 0.19 to 0.99; P=0.04). The effects of treatment were similar in both CD4 cell strata. The responses of CD4 cells and plasma HIV-1 RNA paralleled the clinical results. CONCLUSIONS Treatment with indinavir, zidovudine, and lamivudine as compared with zidovudine and lamivudine alone significantly slows the progression of HIV-1 disease in patients with 200 CD4 cells or fewer per cubic millimeter and prior exposure to zidovudine.
Collapse
|
1337
|
Abstract
Advances in the understanding of human immunodeficiency virus (HIV) pathogenesis, clinical assessment with viral load testing and the availability of potent combination antiretroviral therapy regimens have led to significant changes in options for HIV-infected patients. From the first approved antiretroviral agent, zidovudine (AZT), through two-drug nucleoside analogue regimens, to the current three-drug combination regimens with protease inhibitors, both the benefits of therapy and the complexities of therapy continue to increase. With the clinical benefits come associated lifestyle constraints and, thus, the impact and assessment of potent antiretroviral therapy on patient quality of life (QoL) becomes increasingly complicated.
Collapse
Affiliation(s)
- R M Gulick
- Division of Infectious Disease, New York University School of Medicine, NY 10016, USA
| |
Collapse
|